A recent study conducted at the University Hospital of Quebec City aimed to assess the performance of the preoperative plasma tumor markers, HE4 and CA125, in predicting cancer mortality in women with epithelial ovarian cancer (EOC). The gene discussed is MUC16; the disease is ovarian carcinoma.